GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Notes Receivable

I-MAB (IMAB) Notes Receivable : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB Notes Receivable?

I-MAB's Notes Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.

I-MAB Notes Receivable Historical Data

The historical data trend for I-MAB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Notes Receivable Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial - - - - -

I-MAB Quarterly Data
Dec17 Jun18 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

I-MAB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

I-MAB Notes Receivable Related Terms

Thank you for viewing the detailed overview of I-MAB's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Notes Receivable
Comparable Companies
ACET DOMH EPIX NTRB CRBP ACRV JSPR MNOV VANI ABOS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
0VY:Germany
Address
2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
Website
https://www.i-mabbiopharma.com
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).